151 related articles for article (PubMed ID: 6590568)
1. Induction of terminal differentiation in human K562 erythroleukemia cells by arabinofuranosylcytosine.
Luisi-DeLuca C; Mitchell T; Spriggs D; Kufe DW
J Clin Invest; 1984 Sep; 74(3):821-7. PubMed ID: 6590568
[TBL] [Abstract][Full Text] [Related]
2. Effects of 1-beta-D-arabinofuranosylcytosine and phorbol ester on differentiation of human K562 erythroleukemia cells.
Watanabe T; Mitchell T; Sariban E; Sabbath K; Griffin J; Kufe D
Mol Pharmacol; 1985 Jun; 27(6):683-8. PubMed ID: 3858662
[TBL] [Abstract][Full Text] [Related]
3. Hemoglobin induction by Ara-C in human erythroleukemic cells (K562) is cell-cycle dependent.
Wanda PE; Walker MM
Leuk Res; 1989; 13(8):683-8. PubMed ID: 2796376
[TBL] [Abstract][Full Text] [Related]
4. Altered queuine modification of transfer RNA involved in the differentiation of human K562 erythroleukemia cells in the presence of distinct differentiation inducers.
Chen YL; Wu RT
Cancer Res; 1994 Apr; 54(8):2192-8. PubMed ID: 7513611
[TBL] [Abstract][Full Text] [Related]
5. Enhancement by hemin of the sensitivity of K562 human leukemic cells to 1-beta-D-arabinofuranosylcytosine.
Okabe-Kado J; Hayashi M; Honma Y; Hozumi M
Cancer Res; 1986 Mar; 46(3):1239-43. PubMed ID: 3455882
[TBL] [Abstract][Full Text] [Related]
6. Cellular and clinical pharmacology of low-dose ara-C.
Kufe DW; Griffin JD; Spriggs DR
Semin Oncol; 1985 Jun; 12(2 Suppl 3):200-7. PubMed ID: 3925558
[TBL] [Abstract][Full Text] [Related]
7. Isolation and characterization of a deoxycytidine kinase-deficient human promyelocytic leukemic cell line highly resistant to 1-beta-D- arabinofuranosylcytosine.
Bhalla K; Nayak R; Grant S
Cancer Res; 1984 Nov; 44(11):5029-37. PubMed ID: 6091869
[TBL] [Abstract][Full Text] [Related]
8. Potentiation of cytotoxicity of 1-beta-D-arabinofuranosylcytosine for K562 human leukemic cells by cadeguomycin.
Suzuki H; Kim SH; Tanara M; Okazaki K; Okabe T; Wu RT; Tanaka N
Cancer Res; 1987 Feb; 47(3):713-7. PubMed ID: 3467840
[TBL] [Abstract][Full Text] [Related]
9. Potentiation of 1-beta-D-arabinofuranosylcytosine metabolism and cytotoxicity by 2,3-dihydro-1H-imidazolo[1,2-b]pyrazole in the human promyelocytic leukemic cell, HL-60.
Grant S; Bhalla K; Rauscher F; Cadman E
Cancer Res; 1983 Nov; 43(11):5093-100. PubMed ID: 6577943
[TBL] [Abstract][Full Text] [Related]
10. Terminal erythroid differentiation in the K-562 cell line by 1-beta-D-arabinofuranosylcytosine: accompaniment by c-myc messenger RNA decrease.
Bianchi Scarrà GL; Romani M; Coviello DA; Garrè C; Ravazzolo R; Vidali G; Ajmar F
Cancer Res; 1986 Dec; 46(12 Pt 1):6327-32. PubMed ID: 3536078
[TBL] [Abstract][Full Text] [Related]
11. Essential role of c-myc in ara-C-induced differentiation of human erythroleukemia cells.
Baker SJ; Pawlita M; Leutz A; Hoelzer D
Leukemia; 1994 Aug; 8(8):1309-17. PubMed ID: 8057666
[TBL] [Abstract][Full Text] [Related]
12. Effect of antimetabolites and thymidine blockage on the induction of differentiation of HL-60 cells by retinoic acid or 1 alpha,25-dihydroxyvitamin D3.
Ishikura H; Okazaki T; Mochizuki T; Izumi Y; Tashima M; Sawada H; Uchino H
Exp Hematol; 1985 Nov; 13(10):981-8. PubMed ID: 3932088
[TBL] [Abstract][Full Text] [Related]
13. Effects of tiazofurin on globin and proto-oncogene expression in K562 erythroleukemia cells.
Kharbanda SM; Miyazaki K; Takeyama H; Sherman ML; Spriggs DR; Carney WP; Kufe DW
Cancer Commun; 1989; 1(3):191-7. PubMed ID: 2639729
[TBL] [Abstract][Full Text] [Related]
14. Effect of ara-A on differentiation and proliferation of HL-60 cells.
Munroe D; Sugiura M; Griffin J; Kufe D
Leuk Res; 1984; 8(3):355-61. PubMed ID: 6589455
[TBL] [Abstract][Full Text] [Related]
15. Isolation and characterization of a K562 cell line resistant to 1-beta-D-arabinofuranosylcytosine-mediated erythroid induction.
Biancha Scarrà G; Fiorentini P; Gambari R; Nastruzzi C; Barbieri R; Sessarego M; Ravazzolo R; Garrè C
Exp Hematol; 1989 Sep; 17(8):859-64. PubMed ID: 2475359
[TBL] [Abstract][Full Text] [Related]
16. Induction to erythroid differentiation of K562 cells by 1-beta-D-arabinofuranosylcytosine is inhibited by iron chelators: reversion by treatment with hemin.
Feriotto G; Nastruzzi C; Barbieri R; Gambari R
Blut; 1988 Jul; 57(1):25-30. PubMed ID: 3164639
[TBL] [Abstract][Full Text] [Related]
17. Hemin enhances the sensitivity of erythroleukemia cells to 1-beta-D-arabinofuranosylcytosine by both activation of deoxycytidine kinase and reduction of cytidine deaminase activity.
Honma Y; Onozuka Y; Okabe-Kado J; Kasukabe T; Hozumi M
Cancer Res; 1991 Sep; 51(17):4535-8. PubMed ID: 1873797
[TBL] [Abstract][Full Text] [Related]
18. In K562 leukemia cells treated with doxorubicin and hemin, a decrease in c-myc mRNA expression correlates with loss of self-renewal capability but not with erythroid differentiation.
Toffoli G; Viel A; Bevilacqua C; Maestro R; Tumiotto L; Boiocchi M
Leuk Res; 1989; 13(4):279-87. PubMed ID: 2654492
[TBL] [Abstract][Full Text] [Related]
19. Enforced expression of Bcl-XS induces differentiation and sensitizes chronic myelogenous leukemia-blast crisis K562 cells to 1-beta-D-arabinofuranosylcytosine-mediated differentiation and apoptosis.
Ray S; Bullock G; Nuñez G; Tang C; Ibrado AM; Huang Y; Bhalla K
Cell Growth Differ; 1996 Dec; 7(12):1617-23. PubMed ID: 8959329
[TBL] [Abstract][Full Text] [Related]
20. Terminal differentiation of the human promyelocytic leukemia cell line, HL-60, in the absence of cell proliferation.
Ferrero D; Tarella C; Gallo E; Ruscetti FW; Breitman TR
Cancer Res; 1982 Nov; 42(11):4421-6. PubMed ID: 6957259
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
